Lilly Doubles Down on Eye Diseases, Adding to BD Spree

Leave a Comment / By /

MeiraGTx Holdings is licensing a genetic eye disease medicine to Eli Lilly in a deal worth up to $475 million.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top